1. Home
  2. CCCC vs UIS Comparison

CCCC vs UIS Comparison

Compare CCCC & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCCC
  • UIS
  • Stock Information
  • Founded
  • CCCC 2015
  • UIS 1942
  • Country
  • CCCC United States
  • UIS United States
  • Employees
  • CCCC N/A
  • UIS N/A
  • Industry
  • CCCC Biotechnology: Pharmaceutical Preparations
  • UIS EDP Services
  • Sector
  • CCCC Health Care
  • UIS Technology
  • Exchange
  • CCCC Nasdaq
  • UIS Nasdaq
  • Market Cap
  • CCCC 104.4M
  • UIS 271.5M
  • IPO Year
  • CCCC 2020
  • UIS N/A
  • Fundamental
  • Price
  • CCCC $2.26
  • UIS $4.25
  • Analyst Decision
  • CCCC Buy
  • UIS Hold
  • Analyst Count
  • CCCC 3
  • UIS 1
  • Target Price
  • CCCC $12.00
  • UIS $6.50
  • AVG Volume (30 Days)
  • CCCC 1.6M
  • UIS 686.9K
  • Earning Date
  • CCCC 07-31-2025
  • UIS 08-04-2025
  • Dividend Yield
  • CCCC N/A
  • UIS N/A
  • EPS Growth
  • CCCC N/A
  • UIS N/A
  • EPS
  • CCCC N/A
  • UIS N/A
  • Revenue
  • CCCC $39,783,000.00
  • UIS $1,952,700,000.00
  • Revenue This Year
  • CCCC N/A
  • UIS N/A
  • Revenue Next Year
  • CCCC N/A
  • UIS $3.79
  • P/E Ratio
  • CCCC N/A
  • UIS N/A
  • Revenue Growth
  • CCCC 98.56
  • UIS N/A
  • 52 Week Low
  • CCCC $1.09
  • UIS $3.32
  • 52 Week High
  • CCCC $7.66
  • UIS $8.93
  • Technical
  • Relative Strength Index (RSI)
  • CCCC 63.62
  • UIS 42.86
  • Support Level
  • CCCC $1.36
  • UIS $4.34
  • Resistance Level
  • CCCC $2.17
  • UIS $5.08
  • Average True Range (ATR)
  • CCCC 0.15
  • UIS 0.19
  • MACD
  • CCCC 0.05
  • UIS -0.01
  • Stochastic Oscillator
  • CCCC 67.11
  • UIS 39.45

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.

Share on Social Networks: